Similar findings were found for LA-based nanodrug systems (5-FU-LA@PPL) which increased chemosensitivity, the combinational compatibility of 5-fluorouracil and oxaliplatin, and the suppressed tumor-resided Fn-associated CRC in the in vitro and in vivo colorectal cancer (HT-29) xenograft model [133]. This evidence concerns the gene FN1 and colorectal carcinoma.